NEW HAVEN, Conn., Sept. 28, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has completed Phase 1a of its ongoing clinical trial of ACH-1625, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, and has begun dosing HCV-infected patients in the Phase 1b segment of the trial.
